Johnson & Johnson (JNJ)

JNJ Income Statement

Revenue, expenses, and profitability analysis

JNJ Quarterly Income Statement (USD)

Quarterly Report	TTM	03/29/2026	12/28/2025	09/28/2025	06/29/2025	03/30/2025	12/29/2024	09/29/2024	06/30/2024
Gross Profit	66.604B	17.203B	16.596B	16.690B	16.115B	14.536B	15.392B	15.508B	15.578B
Revenue	96.362B	24.062B	24.564B	23.993B	23.743B	21.893B	22.520B	22.471B	22.447B
Cost of Goods Sold	29.758B	6.859B	7.968B	7.303B	7.628B	7.357B	7.128B	6.963B	6.869B
Gross Profit Margin	71.5%	71.5%	67.6%	69.6%	67.9%	66.4%	68.3%	69.0%	69.4%
Total Operating Expenses	40.712B	10.808B	11.005B	9.594B	9.305B	8.237B	11.551B	10.230B	8.921B
Research & Development	14.967B	3.527B	4.252B	3.672B	3.516B	3.225B	5.298B	4.952B	3.440B
Selling, General & Administrative	24.498B	6.034B	6.753B	5.922B	5.789B	5.012B	6.253B	5.278B	5.481B
Operating Income (EBIT)	25.892B	6.395B	5.591B	7.096B	6.810B	6.299B	3.841B	5.278B	6.657B
Operating Margin	26.6%	26.6%	22.8%	29.6%	28.7%	28.8%	17.1%	23.5%	29.7%
Income Before Tax (EBT)	24.940B	5.990B	4.966B	7.493B	6.491B	13.631B	3.887B	3.338B	5.748B
Interest Income	724.000M	—	237.000M	227.000M	260.000M	332.000M	281.000M	292.000M	395.000M
Interest Expense	810.000M	43.000M	214.000M	245.000M	308.000M	204.000M	137.000M	193.000M	270.000M
Other Income/Expense	-952.000M	-405.000M	-625.000M	397.000M	-319.000M	7.332B	46.000M	-1.940B	-909.000M
Net Income	21.040B	5.235B	5.116B	5.152B	5.537B	10.999B	3.431B	2.694B	4.686B
Income Tax Expense	3.900B	755.000M	-150.000M	2.341B	954.000M	2.632B	456.000M	644.000M	1.062B
Net Profit Margin	21.8%	21.8%	20.8%	21.5%	23.3%	50.2%	15.2%	12.0%	20.9%
EBITDA	31.616B	6.395B	7.191B	9.288B	8.742B	15.607B	5.920B	5.377B	7.800B
EBITDA Margin	26.6%	26.6%	29.3%	38.7%	36.8%	71.3%	26.3%	23.9%	34.7%
Depreciation & Amortization	5.731B	0.00	2.011B	1.777B	1.943B	1.772B	1.896B	1.846B	1.782B
EPS Basic	8.67	2.14	2.10	2.14	2.29	4.57	1.43	1.12	1.95
EPS Diluted	8.65	2.14	2.10	2.12	2.29	4.54	1.41	1.11	1.93
Shares Outstanding	2.445B	2.445B	2.429B	2.429B	2.419B	2.406B	2.407B	2.407B	2.407B
Diluted Shares Outstanding	2.445B	2.445B	2.439B	2.429B	2.419B	2.424B	2.427B	2.428B	2.422B

JNJ Annual Income Statement (USD)

Annual Report	12/28/2025	12/29/2024	12/31/2023	01/01/2023	01/02/2022	01/03/2021	12/31/2019	12/31/2018
Gross Profit	68.558B	61.350B	58.606B	55.394B	55.338B	54.157B	54.503B	54.490B
Revenue	94.193B	88.821B	85.159B	79.990B	78.740B	82.584B	82.059B	81.581B
Cost of Goods Sold	25.635B	27.471B	26.553B	24.596B	23.402B	28.427B	27.556B	27.091B
Gross Profit Margin	72.8%	69.1%	68.8%	69.3%	70.3%	65.6%	66.4%	66.8%
Total Operating Expenses	42.962B	39.201B	35.197B	34.381B	34.395B	34.424B	33.533B	33.315B
Research & Development	14.665B	17.232B	15.085B	14.135B	14.277B	12.340B	11.355B	10.775B
Selling, General & Administrative	23.676B	21.969B	20.112B	20.246B	20.118B	22.084B	22.178B	22.540B
Operating Income (EBIT)	25.596B	22.149B	23.409B	21.013B	20.943B	19.733B	20.970B	21.175B
Operating Margin	27.2%	24.9%	27.5%	26.3%	26.6%	23.9%	25.6%	26.0%
Income Before Tax (EBT)	32.581B	16.687B	15.062B	19.359B	19.178B	16.497B	17.328B	17.999B
Interest Income	1.056B	1.332B	1.261B	490.000M	53.000M	111.000M	357.000M	611.000M
Interest Expense	971.000M	755.000M	772.000M	276.000M	183.000M	201.000M	318.000M	1.005B
Other Income/Expense	6.985B	-5.462B	-8.347B	-1.654B	-1.765B	-3.236B	-3.642B	-3.176B
Net Income	26.804B	14.066B	35.153B	17.941B	20.878B	14.714B	15.119B	15.297B
Income Tax Expense	5.777B	2.621B	1.736B	2.989B	1.377B	1.783B	2.209B	2.702B
Net Profit Margin	28.5%	15.8%	41.3%	22.4%	26.5%	17.8%	18.4%	18.8%
EBITDA	41.055B	24.781B	23.320B	26.605B	26.751B	23.929B	24.655B	25.933B
EBITDA Margin	43.6%	27.9%	27.4%	33.3%	34.0%	29.0%	30.0%	31.8%
Depreciation & Amortization	7.503B	7.339B	7.486B	6.970B	7.390B	7.231B	7.009B	6.929B
EPS Basic	11.03	5.84	13.88	6.83	7.93	5.59	5.74	5.75
EPS Diluted	11.03	5.79	13.72	6.73	7.81	5.51	5.63	5.61
Shares Outstanding	2.429B	2.407B	2.534B	2.614B	2.629B	2.633B	2.633B	2.662B
Diluted Shares Outstanding	2.429B	2.429B	2.560B	2.664B	2.674B	2.671B	2.684B	2.729B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Johnson & Johnson

Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.

New Brunswick, NJ

138,100 employees

www.jnj.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Joaquin Duato

View full financials